Allergan Announces $300 Million Settlement for Loestrin Litigation

January 13, 2020

Allergan reached a $300 million settlement to resolve a class action lawsuit over the oral contraceptives Loestrin 24 Fe (norethindrone acetate, ethinyl estradiol, and ferrous fumarate) and Minastrin 24 Fe (norethindrone acetate and ethinyl estradiol/ferrous fumarate).

Buyers of the contraceptives sued two Allergan subsidiaries, Warner Chilcott and Watson, in federal court alleging that the companies paid generic drugmakers to delay marketing generic versions of the drug. The cases were consolidated in the U.S. District Court for Rhode Island.

Warner Chilcott and Watson will pay a combined $300 million to direct and indirect purchasers of the contraceptives. The settlement, which is subject to court approval, makes no admission of wrongdoing.

View today's stories